| Ytd | -54.61% | |
| 1y | -20.50% |
| Open | 1.25 | Prev Close | 1.29 | Low | 1.25 | High | 1.32 | Mkt Cap | 80.61M |
| Vol | 1.28M | Avg Vol | 963.94K | EPS | -1.19 | P/E | N/A | Forward P/E | -5.04 |
| Beta | -0.31 | Short Ratio | 1.93 | Inst. Own | 44.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 09-19 | 50-d Avg | 2.18 | 200-d Avg | 2.43 | 1yr Est | 7.00 |
CNTB News
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) w
Canaccord Genuity analyst Edward Nash maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study fo
Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular ses
BTIG analyst Julian Harrison reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and main
Connect Biopharma Holdings Limited (NASDAQ:CNTB) stock hit its 52-week low on Tuesday after releasin
Connect Biopharma asthma drug rademikibart misses primary endpoint but shows improved lung function
Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday
Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clin
– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to plac
Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday'
SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Con
Gainers Autonomix Medical (NASDAQ:AMIX) stock moved upwards by 142.1% to $13.0 during Monday's
– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been assigned
CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster
Oppenheimer analyst Mazahir Alimohamed initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB
Piper Sandler analyst Biren Amin initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with
HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) w
– On track to also complete enrollment in the Seabreeze STAT COPD study this month –– Expect to repo
– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to rep
Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Ana
Canaccord Genuity analyst Edward Nash initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB)
Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart p
Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNT
SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Conne
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.34) per share which missed th
– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned ba
Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phas
The independent DMC reviewed interim data based on a pre-specified analysis of treatment failure at
SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Con
Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.27) per share which beat the
– Released positive topline data from Phase 1 study of IV rademikibart in patients with asthma or CO
BTIG analyst Julian Harrison reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and main
Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Upda
– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pu
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, w
Funding from new and existing investors extends anticipated cash runway into the second half of 2027
– Rademikibart achieved rapid, durable efficacy results across all key endpoints through 52 weeks, w
– Rademikibart administered as a single 300 mg 2-minute IV push to asthma and chronic obstructive pu
Shares of Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) have ear
Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect, or the Company), a cli
SAN DIEGO, March 10, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Con
– Announced new data demonstrating a unique mechanism of action supporting the best-in-class potenti
